Veracyte, Inc. (NASDAQ:VCYT – Get Free Report) has received a consensus rating of “Moderate Buy” from the ten research firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $40.90.
VCYT has been the subject of several recent analyst reports. Stephens reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Veracyte in a research note on Wednesday, March 26th. Needham & Company LLC lowered their target price on shares of Veracyte from $51.00 to $41.00 and set a “buy” rating for the company in a research note on Thursday, May 8th. Craig Hallum initiated coverage on shares of Veracyte in a research report on Thursday, March 20th. They set a “buy” rating and a $45.00 price objective for the company. UBS Group lowered their price objective on shares of Veracyte from $49.00 to $42.00 and set a “buy” rating for the company in a research report on Thursday, May 8th. Finally, Guggenheim lowered their price objective on shares of Veracyte from $45.00 to $37.00 and set a “buy” rating for the company in a research report on Wednesday, April 9th.
Get Our Latest Analysis on Veracyte
Veracyte Stock Performance
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in VCYT. Rhumbline Advisers boosted its holdings in Veracyte by 0.6% during the fourth quarter. Rhumbline Advisers now owns 123,324 shares of the biotechnology company’s stock worth $4,884,000 after purchasing an additional 675 shares during the last quarter. Principal Securities Inc. lifted its stake in Veracyte by 34.1% in the fourth quarter. Principal Securities Inc. now owns 1,909 shares of the biotechnology company’s stock valued at $76,000 after acquiring an additional 485 shares during the last quarter. Principal Financial Group Inc. lifted its stake in Veracyte by 6.8% in the fourth quarter. Principal Financial Group Inc. now owns 32,560 shares of the biotechnology company’s stock valued at $1,289,000 after acquiring an additional 2,074 shares during the last quarter. D.A. Davidson & CO. acquired a new stake in Veracyte in the fourth quarter valued at $925,000. Finally, Venturi Wealth Management LLC acquired a new stake in Veracyte in the fourth quarter valued at $91,000.
Veracyte Company Profile
Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.
Featured Articles
- Five stocks we like better than Veracyte
- Quiet Period Expirations Explained
- Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.